Sera Prognostics, Inc. (SERA) stock

SERANasdaqServices-Medical LaboratoriesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30

$2.01+0.03 (+1.52%)

Close on Nov 13, 2026Market cap $79.29MP/E –Yield –

Sera Prognostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Sera Prognostics's price to sales ratio was 482.8× on May 30, 2025, against 438.9× a year earlier.

Period	Period end	Value	Change (pts)
2025	May 30, 2025	482.8×	+300.0
2023	Nov 30, 2023	182.8×	−225.2
2021	Oct 29, 2021	408.1×	–

Parsed from the XBRL in Sera Prognostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SERA.

Revenue growth1.1% · median -10.6%

Gross margin-86.5% · median 29.1%

Operating margin-38755.2% · median -4059.4%

Net margin-34866.7% · median -5885.3%

Advertisement
300 × 250

See a number that looks wrong?